Successful External Assessment of Genedrive® Hepatitis C Test

Partner 3 EPISTEM has announced on February 18th that its Genedrive® point of care Hepatitis C ("HCV") test has successfully completed its first external assessment.The assessment was conducted on reference material and patient samples at the Institut Pasteur, Paris, and its success allows clinical trials of the HCV test to commence, in anticipation of regulatory approval and market launch in the EU during 2017.

For more information: Epistem 

 


europe  

PoC-HCV is a European research project supported
by the European Commission (Grant agreement n° 601851).